CD

Carl Decicco

Partner at Flagship Pioneering

New Hope, Pennsylvania

Overview 

Carl Decicco is a Pharmaceutical Executive based in New Hope, Pennsylvania, with a background in Medicinal Chemistry and Drug Discovery. He has held key leadership roles at Flagship Pioneering and Bristol-Myers Squibb, including serving as Senior Vice President and Head of Discovery, showcasing a strong track record in drug development and molecular sciences. Decicco's career highlights include his role as Chief Scientific Officer at Foghorn Therapeutics, Inc, and his leadership in advancing drug discovery at Bristol-Myers Squibb as Senior Vice President of Molecular Sciences, demonstrating expertise in leading innovative research and development initiatives in the pharmaceutical industry.

Work Experience 

FP

Flagship Pioneering

  • Partner

    2018 - Current

Flagship Pioneering is a venture capital firm that invests in life sciences and healthcare companies.

flagshippioneering.com
FT

Foghorn Therapeutics, Inc

  • Chief Scientific Officer

    2018 - 2022

Foghorn Therapeutics is developing therapies based on a system that directs which genes our cells express,

Raised $221,000,000.00 from Irving Investors, Invus, Casdin Capital and Flagship Pioneering.

foghorntx.com
BS

Bristol-Myers Squibb

  • Senior Vice President, Head of Discovery

    2013 - 2018

Bristol-Myers Squibb engages in the discovery, development, licensing, manufacturing, marketing, distribution and sale of pharmaceuticals.

Raised $23,580,000,000.00 from RA Capital Management, OUP (Osage University Partners), Aperture Venture Partners, Greg Bailey, Connecticut Innovations, Knoll Capital Management, Vivo Capital, Venrock, Litmore Capital and Carl Icahn.

bms.com
BS

Bristol-Myers Squibb

  • Senior Vice President, Molecular Sciences

    2010 - 2013

  • Vice President, Discovery Chemistry/Molecular Sciences

    2002 - 2010

Bristol-Myers Squibb engages in the discovery, development, licensing, manufacturing, marketing, distribution and sale of pharmaceuticals.

Raised $23,580,000,000.00 from RA Capital Management, OUP (Osage University Partners), Aperture Venture Partners, Greg Bailey, Connecticut Innovations, Knoll Capital Management, Vivo Capital, Venrock, Litmore Capital and Carl Icahn.

bms.com

Education 

Articles About Carl

Relevant Websites